Form 4: AN2 Therapeutics Executive Sells Shares to Cover Tax Obligations

Sanjay Chanda, Chief Development Officer at AN2 Therapeutics, sold 2,957 shares to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Sanjay Chanda, the Chief Development Officer of AN2 Therapeutics, sold 2,957 shares of common stock on January 3, 2025, at a price of $1.341 per share.
• This sale was to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
• Following the transaction, Chanda beneficially owns 29,824 shares, which includes 20,625 RSUs that vest over three years from January 1, 2025.
• The total also includes 2,224 shares purchased on March 31, 2024, and 2,322 shares purchased on September 30, 2024, under the company's Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• Many companies use RSUs as part of their compensation packages, leading to similar transactions when vesting occurs.
• The sale price of $1.341 per share is specific to AN2 Therapeutics and would need to be compared to other similar biotech companies to assess its relative value.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally not considered a significant event.

Key Dates

Keywords

AN2 Therapeutics, Sanjay Chanda, stock sale, restricted stock units, RSU, tax obligations, insider trading, employee stock purchase plan, ESPP